"Despite the unanimous backing of a Food and Drug Administration (FDA) advisory committee back in May, Novo Nordisk has announced there is to be a 3-month delay on a decision regarding US approval of its new injectable product, IDegLira, "...
Severe hypoglycemic reactions with coma, seizure, or other neurological impairment may occur and constitute medical emergencies requiring immediate hospitalization. Hypoglycemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring may continue until the physician is assured that the patient is out of danger. Patients should be closely monitored for a minimum of 24 to 48 hours, since hypoglycemia may recur after apparent clinical recovery. There is no evidence that PRANDIN is dialyzable using hemodialysis.
PRANDIN is contraindicated in patients with:
- Concomitant use of gemfibrozil [see DRUG INTERACTIONS]
- Known hypersensitivity to repaglinide or any inactive ingredients
Last reviewed on RxList: 3/13/2017
Additional Prandin Information
Prandin - User Reviews
Prandin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.